Results 161 to 170 of about 65,815 (207)

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas. [PDF]

Clin Transl Sci
Chen WS, Lin TM, Chang YS, Shen YC, Hsu HC, Kuo TT, Chen SC, Chen JH, Chang CC.   +8 more
europepmc   +1 more source

Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study. [PDF]

BMJ Open Diabetes Res Care
Thompson W, Yu B, Porter J, Fang J, Ferreira-Legere LE, Austin PC, Jackevicius CA, Ross H, Lee DS, Weisman A, Farkouh ME, Gershon AS, Atzema CL, Kwong JC, Ha A, Džavík V, Udell JA.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dipeptidyl peptidase-4 inhibitors

Reactions Weekly, 2021
The dipeptidyl peptidase 4 (DPP-4) inhibitor has become a popular anti-diabetes medication since its introduction in 2006. They are small molecules that specifically bind to the catalytic domain of DPP-4, which consequently prevents the enzymatic inactivation of incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide)
Yoo Hyung Kim, Young Min Cho
openaire   +2 more sources

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Kimberly C. McKeirnan, Joshua J. Neumiller   +1 more
  +4 more sources

Highlight: Dipeptidyl peptidase 4 and related proteins

Biological Chemistry, 2011
No abstract ...
Torsten, Hoffmann, Hans-Ulrich, Demuth
openaire   +2 more sources

Dipeptidyl peptidase-4 inhibitors

2016
Dipeptidyl peptidase (DPP)-4 inhibitors inhibit the activity of the enzyme responsible for the initial rapid degradation of the incretin hormones, thereby enhancing their antihyperglycemic effects.
openaire   +1 more source

Renal outcomes with dipeptidyl peptidase-4 inhibitors

Diabetes & Metabolism, 2018
Dipeptidyl peptidase-4 inhibitors (DPP-4is) are increasingly being used in the management of type 2 diabetes (T2D). The present review summarizes the current knowledge of the effects of DPP-4is on renal outcomes by analyzing the experimental preclinical data, the effects of DPP-4is on urinary albumin-creatinine ratios (UACRs) and estimated glomerular ...
Scheen, André, DELANAYE, Pierre
openaire   +3 more sources

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

Drugs, 2011
The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of endogenously released incretin hormones, represent a new therapeutic approach to the management of type 2 diabetes mellitus. The 'first-in-class' DPP-4 inhibitor, sitagliptin, was approved in
R. Baetta, A. Corsini
openaire   +2 more sources